| Primary |
| Acute Promyelocytic Leukaemia |
69.0% |
| Acute Myeloid Leukaemia |
13.6% |
| Myelodysplastic Syndrome |
7.8% |
| Multiple Myeloma |
2.8% |
| Leukaemic Infiltration Extramedullary |
0.7% |
| Prophylaxis |
0.7% |
| Myelofibrosis |
0.6% |
| Myeloid Leukaemia |
0.6% |
| Convulsion Prophylaxis |
0.5% |
| Glioblastoma Multiforme |
0.5% |
| Herpes Zoster |
0.5% |
| Hypertension |
0.5% |
| Depression |
0.4% |
| Headache |
0.4% |
| Neuroblastoma |
0.4% |
| Pain |
0.4% |
| Astrocytoma Malignant |
0.2% |
| Chronic Myelomonocytic Leukaemia |
0.2% |
| Endometrial Cancer |
0.2% |
| Gastritis Prophylaxis |
0.2% |
|
| White Blood Cell Count Decreased |
21.5% |
| Weight Increased |
9.1% |
| Ventricular Tachycardia |
6.2% |
| Pancytopenia |
5.8% |
| Hepatic Function Abnormal |
4.4% |
| Rash |
4.4% |
| Pneumonia |
4.0% |
| Septic Shock |
4.0% |
| Vomiting |
4.0% |
| Pleural Effusion |
3.6% |
| Sepsis |
3.6% |
| Electrocardiogram Qt Prolonged |
3.3% |
| Febrile Neutropenia |
3.3% |
| Neutropenia |
3.3% |
| Pyrexia |
3.3% |
| Renal Failure |
3.3% |
| Respiratory Failure |
3.3% |
| Thrombocytopenia |
3.3% |
| Ventricular Extrasystoles |
3.3% |
| Leukopenia |
2.9% |
|
| Secondary |
| Acute Promyelocytic Leukaemia |
58.1% |
| Myelodysplastic Syndrome |
12.1% |
| Acute Myeloid Leukaemia |
9.5% |
| Product Used For Unknown Indication |
8.3% |
| Multiple Myeloma |
2.2% |
| Antiviral Prophylaxis |
1.2% |
| Retinoic Acid Syndrome |
1.2% |
| Sepsis |
1.2% |
| Herpes Zoster |
1.0% |
| Drug Use For Unknown Indication |
0.9% |
| Pain |
0.9% |
| Gastritis Prophylaxis |
0.6% |
| Prophylaxis |
0.6% |
| Arrhythmia |
0.4% |
| Acquired Immunodeficiency Syndrome |
0.3% |
| Constipation Prophylaxis |
0.3% |
| Convulsion Prophylaxis |
0.3% |
| Dyspnoea |
0.3% |
| Gastrooesophageal Reflux Prophylaxis |
0.3% |
| Hypertension |
0.3% |
|
| White Blood Cell Count Decreased |
23.4% |
| Gamma-glutamyltransferase Increased |
9.1% |
| Leukopenia |
7.8% |
| Sepsis |
7.8% |
| Weight Increased |
7.8% |
| Rash |
5.2% |
| Vomiting |
5.2% |
| Hepatic Function Abnormal |
3.9% |
| Thrombocytopenia |
3.9% |
| Neutropenia |
3.2% |
| Ventricular Tachycardia |
3.2% |
| Blood Fibrinogen Decreased |
2.6% |
| Pericardial Effusion |
2.6% |
| Pyrexia |
2.6% |
| Aspartate Aminotransferase Increased |
1.9% |
| Cataract |
1.9% |
| Febrile Neutropenia |
1.9% |
| Neutrophil Count Decreased |
1.9% |
| Renal Impairment |
1.9% |
| Somnolence |
1.9% |
|
| Concomitant |
| Multiple Myeloma |
20.7% |
| Prophylaxis |
17.4% |
| Chemotherapy |
8.7% |
| Depression |
8.7% |
| Anxiety |
6.5% |
| Acute Myeloid Leukaemia |
5.4% |
| Hypertension |
5.4% |
| Acute Promyelocytic Leukaemia |
4.3% |
| Radiotherapy |
4.3% |
| Gastrooesophageal Reflux Disease |
3.3% |
| Myelodysplastic Syndrome |
3.3% |
| Diabetes Mellitus |
2.2% |
| Pain |
2.2% |
| Convulsion |
1.1% |
| Dyslipidaemia |
1.1% |
| Hyperlipidaemia |
1.1% |
| Lower Respiratory Tract Infection |
1.1% |
| Nausea |
1.1% |
| Pulmonary Hypertension |
1.1% |
| Pyrexia |
1.1% |
|
| Wound Drainage |
25.0% |
| Myalgia |
8.3% |
| Myocardial Infarction |
8.3% |
| Pain |
8.3% |
| Tendonitis |
8.3% |
| Thrombocytopenia |
8.3% |
| Tooth Extraction |
8.3% |
| Type I Hypersensitivity |
8.3% |
| Urinary Retention |
8.3% |
| Vision Blurred |
8.3% |
|
| Interacting |
| Acute Myeloid Leukaemia |
100.0% |
|
|
